ATE273716T1 - Verfahren zur herstellung eines arzneimittelkomplexes - Google Patents
Verfahren zur herstellung eines arzneimittelkomplexesInfo
- Publication number
- ATE273716T1 ATE273716T1 AT97924326T AT97924326T ATE273716T1 AT E273716 T1 ATE273716 T1 AT E273716T1 AT 97924326 T AT97924326 T AT 97924326T AT 97924326 T AT97924326 T AT 97924326T AT E273716 T1 ATE273716 T1 AT E273716T1
- Authority
- AT
- Austria
- Prior art keywords
- spacer
- drug compound
- bound
- carboxyl groups
- polysaccharide derivative
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 8
- 229940079593 drug Drugs 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000006850 spacer group Chemical group 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 150000004676 glycans Chemical class 0.000 abstract 4
- 229920001282 polysaccharide Polymers 0.000 abstract 4
- 239000005017 polysaccharide Substances 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 238000006243 chemical reaction Methods 0.000 abstract 2
- -1 amine salt Chemical class 0.000 abstract 1
- 125000000686 lactone group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007086 side reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14452296 | 1996-06-06 | ||
| PCT/JP1997/001915 WO1997046261A1 (fr) | 1996-06-06 | 1997-06-05 | Procede de fabrication de complexes medicamenteux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE273716T1 true ATE273716T1 (de) | 2004-09-15 |
Family
ID=15364300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97924326T ATE273716T1 (de) | 1996-06-06 | 1997-06-05 | Verfahren zur herstellung eines arzneimittelkomplexes |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6291671B1 (de) |
| EP (1) | EP0955064B1 (de) |
| JP (1) | JP4137184B2 (de) |
| CN (1) | CN1227034C (de) |
| AT (1) | ATE273716T1 (de) |
| AU (1) | AU723442B2 (de) |
| CA (1) | CA2257233A1 (de) |
| DE (1) | DE69730352T2 (de) |
| DK (1) | DK0955064T3 (de) |
| EA (1) | EA001897B1 (de) |
| ES (1) | ES2229355T3 (de) |
| ID (1) | ID17243A (de) |
| NO (1) | NO323626B1 (de) |
| PT (1) | PT955064E (de) |
| TW (1) | TW409058B (de) |
| WO (1) | WO1997046261A1 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| EA003398B1 (ru) * | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Лекарственный комплекс c полимерным носителем |
| US20030166513A1 (en) * | 2000-06-29 | 2003-09-04 | Akihiro Imura | Dds compound and process for the preparation thereof |
| EP1401875A4 (de) * | 2001-05-04 | 2005-01-26 | Univ Utah Res Found | Hyaluronsäure enthaltende biokonjugate: gezielte abgabe von antikrebsmitteln an krebszellen |
| US20030049253A1 (en) * | 2001-08-08 | 2003-03-13 | Li Frank Q. | Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines |
| US20050169883A1 (en) * | 2002-05-06 | 2005-08-04 | Prestwich Glenn D. | Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents |
| US7691830B2 (en) * | 2005-02-17 | 2010-04-06 | Clive Elson | Method and composition for treatment of a mucosal tissue disorder |
| MX2007013725A (es) | 2005-05-05 | 2008-04-09 | Sensient Flavors Inc | Produccion de beta-glucanos y mananos. |
| WO2007004675A1 (ja) * | 2005-07-06 | 2007-01-11 | Seikagaku Corporation | 薬剤導入光架橋ヒアルロン酸誘導体ゲル |
| ITPD20050242A1 (it) | 2005-08-03 | 2007-02-04 | Fidia Farmaceutici | Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico |
| CN1973902B (zh) * | 2006-12-12 | 2010-11-10 | 东北师范大学 | 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法 |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| WO2011150022A2 (en) | 2010-05-25 | 2011-12-01 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| CA2908993C (en) | 2013-04-10 | 2023-05-23 | Syndevrx, Inc. | Metap2 inhibitors and methods of treating obesity |
| WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| AU2014371934B2 (en) | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| IL310627B2 (en) | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| EP3130608B1 (de) | 2014-04-10 | 2019-09-04 | Daiichi Sankyo Co., Ltd. | (anti-her2-antikörper)-arzneimittelkonjugat |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| ES2893749T3 (es) | 2015-12-10 | 2022-02-10 | Syndevrx Inc | Derivados de fumagilol y polimorfos de los mismos |
| CA3239447A1 (en) | 2016-01-11 | 2017-07-20 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| US11273155B2 (en) | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| JP6679762B2 (ja) | 2017-01-17 | 2020-04-15 | 第一三共株式会社 | 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート |
| TW202532104A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| IL324591A (en) | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
| CA3074208C (en) | 2017-08-31 | 2023-10-03 | Daiichi Sankyo Company, Limited | Novel method for producing antibody-drug conjugate |
| SG11202010496WA (en) | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
| WO2020022475A1 (ja) | 2018-07-27 | 2020-01-30 | 第一三共株式会社 | 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質 |
| CA3108044A1 (en) | 2018-07-31 | 2020-02-06 | Daiichi Sankyo Company, Limited | Treatment of metastatic brain tumor by administration of antibody-drug conjugate |
| JP2022512826A (ja) | 2018-10-26 | 2022-02-07 | シンデブルックス，インコーポレイティド | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 |
| US11555019B2 (en) | 2019-07-10 | 2023-01-17 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5746920A (en) * | 1980-09-03 | 1982-03-17 | Kyosei Seiyaku Kk | Drug for digestive tract |
| DE3152319C2 (de) | 1980-09-03 | 1986-05-07 | Kyosei Pharmaceutical Co., Ltd., Hokkaido | Verwendung einer Lösung eines Salzes der Alginsäure zur Behandlung von Strahlenschäden und Ulcera |
| JPS59220197A (ja) | 1983-05-30 | 1984-12-11 | Snow Brand Milk Prod Co Ltd | 新規な含窒素多糖体およびその製造方法 |
| JP2604930B2 (ja) | 1990-12-14 | 1997-04-30 | 株式会社ディ・ディ・エス研究所 | ヒアルロン酸およびコンドロイチン誘導体 |
| CA2059693C (en) * | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
| JPH0784481B2 (ja) | 1991-02-21 | 1995-09-13 | 株式会社デイ・デイ・エス研究所 | カルボキシメチルマンノグルカン及びその誘導体 |
| JP3359955B2 (ja) | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| ES2149867T3 (es) | 1993-02-26 | 2000-11-16 | Drug Delivery System Inst Ltd | Derivados de polisacaridos y soportes para farmacos. |
| JPH0784481A (ja) | 1993-06-26 | 1995-03-31 | Ricoh Co Ltd | 画像形成装置 |
| SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| US6299881B1 (en) * | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
-
1997
- 1997-05-31 TW TW086107456A patent/TW409058B/zh not_active IP Right Cessation
- 1997-06-05 EP EP97924326A patent/EP0955064B1/de not_active Expired - Lifetime
- 1997-06-05 CA CA002257233A patent/CA2257233A1/en not_active Abandoned
- 1997-06-05 ID IDP971929A patent/ID17243A/id unknown
- 1997-06-05 AT AT97924326T patent/ATE273716T1/de not_active IP Right Cessation
- 1997-06-05 ES ES97924326T patent/ES2229355T3/es not_active Expired - Lifetime
- 1997-06-05 DK DK97924326T patent/DK0955064T3/da active
- 1997-06-05 DE DE69730352T patent/DE69730352T2/de not_active Expired - Lifetime
- 1997-06-05 US US09/147,341 patent/US6291671B1/en not_active Expired - Fee Related
- 1997-06-05 JP JP50042298A patent/JP4137184B2/ja not_active Expired - Fee Related
- 1997-06-05 AU AU29788/97A patent/AU723442B2/en not_active Ceased
- 1997-06-05 PT PT97924326T patent/PT955064E/pt unknown
- 1997-06-05 EA EA199900002A patent/EA001897B1/ru not_active IP Right Cessation
- 1997-06-05 WO PCT/JP1997/001915 patent/WO1997046261A1/ja not_active Ceased
- 1997-06-05 CN CNB971971153A patent/CN1227034C/zh not_active Expired - Fee Related
-
1998
- 1998-12-04 NO NO19985667A patent/NO323626B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2978897A (en) | 1998-01-05 |
| ID17243A (id) | 1997-12-11 |
| ES2229355T3 (es) | 2005-04-16 |
| EA199900002A1 (ru) | 1999-08-26 |
| WO1997046261A1 (fr) | 1997-12-11 |
| NO985667D0 (no) | 1998-12-04 |
| NO985667L (no) | 1999-02-04 |
| EP0955064A4 (de) | 2000-12-06 |
| NO323626B1 (no) | 2007-06-18 |
| US6291671B1 (en) | 2001-09-18 |
| AU723442B2 (en) | 2000-08-24 |
| DE69730352D1 (de) | 2004-09-23 |
| CN1227500A (zh) | 1999-09-01 |
| CA2257233A1 (en) | 1997-12-11 |
| EA001897B1 (ru) | 2001-10-22 |
| EP0955064B1 (de) | 2004-08-18 |
| TW409058B (en) | 2000-10-21 |
| JP4137184B2 (ja) | 2008-08-20 |
| DE69730352T2 (de) | 2005-09-08 |
| DK0955064T3 (da) | 2004-12-06 |
| EP0955064A1 (de) | 1999-11-10 |
| PT955064E (pt) | 2004-10-29 |
| CN1227034C (zh) | 2005-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE273716T1 (de) | Verfahren zur herstellung eines arzneimittelkomplexes | |
| ATE121088T1 (de) | Verfahren zur herstellung von imidazo(4,5- c>chinolin-4-aminen. | |
| ATE121414T1 (de) | Verfahren zur herstellung von erythromcin a-oxim oder eines salzes davon. | |
| DE69900462D1 (de) | Konjugate von dns und pns und verfahren zu deren herstellung | |
| DE60031208D1 (de) | Verfahren zur Herstellung von Mikroperlen die fettlösliche Substanzen enthalten | |
| CA2399187A1 (en) | Kahalalide compounds | |
| DE69011880D1 (de) | Verfahren zur Herstellung von L-Aminosäuren durch Fermentation. | |
| FI881496A7 (fi) | Menetelmä aminohappojen valmistamiseksi tai uuttamiseksi lannasta | |
| ATA342186A (de) | Verfahren zur herstellung eines organischen carbonsaeureanhydrids | |
| ATE264290T1 (de) | Verfahren zur herstellung von 5-hydroxy-3-oxo- pentansäure-derivaten | |
| ES436565A1 (es) | Un procedimiento para la preparacion de acidos acetamidope- nicilanicos. | |
| DE68923534D1 (de) | Verfahren zur Herstellung eines organischen Kristalls. | |
| EP1336603A4 (de) | Verfahren zur einführung von aminogruppen und verfahren zur synthese von aminosäuren | |
| ATE205498T1 (de) | Verfahren zur herstellung von kaliumclavulanat | |
| DE69520368D1 (de) | Verfahren zur herstellung von 5-hydroxymethyl-thiazole | |
| ATE167871T1 (de) | Verfahren zur herstellung von vancomycin | |
| ATE189220T1 (de) | Verfahren zur herstellung von 7-(3-amino- sowie 3-aminomethyl-1-pyrrolidinyl)-3-chinolon- carbonsäuren sowie -naphthyridoncarbonsäuren | |
| ATE384067T1 (de) | Verfahren zur herstellung von 3-cephemderivaten | |
| DE3751261D1 (de) | Verfahren zur Herstellung eines Kohlensäureesters. | |
| DE68925951D1 (de) | Chemisches Verfahren zur Herstellung des Antibiotikums L 17392 (Deglukoteicoplanin) und dessen Salze | |
| DE3765370D1 (de) | Verfahren zur herstellung eines o-naphtochinondiazidsulfonsaeureesters. | |
| PT83837A (de) | Verfahren zur herstellung von peptiden unter der verwendung von perchloraten | |
| ATE128456T1 (de) | Verfahren zur herstellung eines alpha-amino- alkohols. | |
| ATE222887T1 (de) | Verfahren zur herstellung von inorganischen salzen von optisch aktiven phenylglycin-derivaten | |
| DE69926642D1 (de) | Verfahren zur herstellung von n-geschützten azetidin-2-carbonsäuren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0955064 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |